期刊文献+

不同剂量氨磺必利治疗精神分裂症阴性症状疗效观察 被引量:8

下载PDF
导出
摘要 目的探讨不同剂量的氨磺必利治疗精神分裂症阴性症状的疗效和安全性。方法精神分裂症患者90例随机分成3组,分别给予氨磺必利片100-300mg/d(低剂量组),400-800mg/d(中等剂量组)和900-1200mg/d(高剂量组)口服治疗12周,在治疗前及治疗后第4、8和12周末采用阳性与阴性症状量表(PANSS)和不良反应症状量表(TESS)评定疗效和安全性。结果在治疗后各周末,3组患者PANSS总分及各因子分较治疗前均有明显下降(P〈0.01),中等剂量组PANSS总分及各因子分均明显低于低剂量组(P〈0.01),低荆量组PANSS阴性症状分与高剂量组差异无统计学意义(P〉0.05);治疗后12周末,中等剂量组PANSS总分及阴性症状分明显低于高剂量组(P〈0.01);3组间不良反应的差异主要体现在锥体外系反应、月经改变或泌乳方面(P〈0.05或P〈0.01),其中高剂量组不良反应发生率较高。结论3组不同剂量的氨磺必利对以阴性症状为主的精神分裂症患者均有疗效,但中等剂量氨磺必利组在3组中的优势更为明显。
出处 《浙江临床医学》 2016年第1期133-134,共2页 Zhejiang Clinical Medical Journal
  • 相关文献

参考文献10

  • 1黄素培,张瑞岭,王来海,潘保中.氨磺必利的药理学进展与临床应用评价[J].中国医院用药评价与分析,2011,11(8):679-683. 被引量:70
  • 2谢少烽.氨磺必利对精神分裂症患者的疗效研究[J].精神医学杂志,2012,25(4):300-302. 被引量:23
  • 3Ahn YM, Lee KY, Kim CE, et al.The acute and long-term effectiveness of amisulpride in patients with schizophrenia: results of a 12-month open-label prospective follow-up study,Hum Psychopharmacol,2011, 26(8): 568-577.
  • 4Muller MJ, Wetzel H, Eich FX, et al.Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia.J Clln Psychopharmacol, 2002, 22(6):554-560.
  • 5Andreasen NC,Olsen S.Negative vs positive schizophrenia:definition and validition.Arch Gen Psychiatry. 1982,39:789.
  • 6Lee SJ, Lee JH, Jung SW, et al. A 6-week, randonfized, multicentre, open-label study comparing efficacy and tolerability of amisulpride at a starting dose of 400 mg/day versus 800 rag/day in patients with acute exacerbations of schizophrenia. Clin Drug Investig, 2012, 32(11): 735-745.
  • 7林涌超,欧文前,李凌恩,张茹.氨磺必利与氯氮平对阴性症状为主的精神分裂症患者临床疗效及生活质量的对照研究[J].中华行为医学与脑科学杂志,2012,21(8):705-708. 被引量:76
  • 8陈妍,陈美娟.氨磺必利在精神分裂症中的研究进展[J].神经疾病与精神卫生,2011,11(1):83-85. 被引量:70
  • 9Kotan Z, Ertepe B, Akkaya C, et al.Metabolic, endocrinologic and cardiac effects of amisulpride: a 24-week follow-up study. Ther Adv Psychopharmacol, 2011, 1(6): 189-196.
  • 10Murphy BP, Stuart AH, Wade D, et al. Efficacy of arnisulpride in treating primary negative symptoms in first-episode psychosis: a pilot study. Hum Psychophamlacol, 2006, 21 (8): 511-517.

二级参考文献87

  • 1翟金国,赵靖平,房茂胜.新型非典型抗精神病药临床应用评价[J].中国新药与临床杂志,2006,25(4):296-301. 被引量:42
  • 2李凌江 杨德森.生活质量综合评定问卷-74.中国心理卫生杂志,1999,:88-100.
  • 3沈渔邨.精神病学.北京:人民卫生出版社,2009:406.
  • 4Nuss P, Tessier C. Antipsychotic medication, functional outcome and quality of life in schizophrenia: focus on amisulpride [ J ]. Curr Med Res Opion,2010,26 (4) :787.
  • 5Kerwin R. From pharmacological profiles to clinical out comes [ J ]. J lnt Clin Psychopharmacol , 2000,15 (4) : 1.
  • 6Trichard C, Paillere-Martinot ML, Attar-Levy D, et al. Binding of antipsychotic drugs to cortical 5-HT2A receptors : a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients [ J ]. Am J Psychiatry, 1998,155 (4) : 505.
  • 7Miguel H E, Rogelio A, Ana F, et al, The effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia:a prospective open-label study [ J]. J BMC Psychiatry,2005,5 ( 3 ) :22.
  • 8Kirschbaum KM, Hiemke C, Schmitt U. Rotarod impairment:catalepsy-like screening test for antipsychotic side effects[J], lnt J Neurosci ,2009 ,119 (10 ) :1509.
  • 9Masdrakis VG, Papadimitrion GN, Papageorgion C, et al. Development of tardive dyskinesia in a patient taking amisulpride [ J ]. J Prog Neuropsychopharmacol Biol Psychiatry,2007,31 (2) :586.
  • 10Fountoulakis KN, Panagiotidis P, Siamouli M, et al, Amisulpride-induced tardive dyskinesia [ J ]. Schizophr Res ,2006,88 ( 1-3 ) :232.

共引文献201

同被引文献46

引证文献8

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部